Clinical Trials Logo

Clinical Trial Summary

The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple Myeloma (MM)


Clinical Trial Description

This first-in-human trial with WVT078 is a dose escalation study whose primary purpose is to characterize the safety, tolerability, and determine recommended dose regimen(s) of WVT078 alone and in combination with WHG626 in subjects with MM who have received two or more standard of care lines of therapy including an IMID, a proteasome inhibitor, and an anti-CD38 agent (if available) and are relapsed and/or refractory to or intolerant of each regimen. In addition, this study will assess preliminary anti-MM response of and characterize the pharmacokinetics and immunogenicity of WVT078 alone and in combination with WHG626. The results of this study will inform the future development of WVT078 alone and in combination with WHG626 as a treatment for relapsed and/or refractory MM. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04123418
Study type Interventional
Source Novartis
Contact
Status Active, not recruiting
Phase Phase 1
Start date December 5, 2019
Completion date December 2, 2024

See also
  Status Clinical Trial Phase
Completed NCT02265731 - Study Evaluating Venetoclax in Subjects With Hematological Malignancies Phase 1/Phase 2
Recruiting NCT05442580 - CART-38 in Adult AML and MM Patients Phase 1
Terminated NCT04178902 - A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma Phase 1
Completed NCT02920697 - Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma Phase 1
Recruiting NCT05908409 - A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies Phase 1/Phase 2
Active, not recruiting NCT04702425 - VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) Phase 1
Completed NCT00710528 - Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies Phase 1
Completed NCT04721002 - Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)
Active, not recruiting NCT02240537 - Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer Phase 1
Active, not recruiting NCT02203643 - Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma. Phase 2
Completed NCT02211014 - An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma Phase 1
Recruiting NCT04649073 - Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma Phase 1/Phase 2
Recruiting NCT03018405 - A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications Phase 1/Phase 2
Terminated NCT01663766 - Phase I Study of Milatuzumab for Graft Versus Host Disease Phase 1
Completed NCT01919086 - Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma Phase 2
Withdrawn NCT05513612 - Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies Phase 1
Completed NCT01413568 - Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies Phase 1/Phase 2
Completed NCT00889798 - Tumor Registry of Lymphatic Neoplasia